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Synthetic Elastase Inhibitors (HL29307) 
Annual Report (April 1, 1990-March 31, 1991) 
James C. Powers, PI 
School of Chemistry and Biochemistry, Georgia Institute of Technology 
Atlanta, GA 30332 
Specific Aims. The major specific aim of our proposed research was the development of a 
synthetic elastase inhibitor which would be useful for the treatment of human emphysema. A variety of 
inhibitor structures were proposed including heterocyclic mechanism-based inhibitors and peptide 
transition state analogs. We proposed to test the specificity of all new inhibitors with other PMN proteases 
such as human leukocyte cathepsin G. A secondary goal of the research was the extension of potent 
inhibitor structures to other serine proteases. We suggested that inhibitor studies would lead to a better 
understanding of the active site structures of the serine proteases involved in connective tissue turnover, 
might produce clinically useful drugs for the treatment of emphysema and related diseases, would 
stimulate the research of medicinal chemists in pharmaceutical companies, and will provide new tools for 
the in vivo and in vitro study of the role of neutrophil and mast cell proteases in a variety of physiological 
processes. 
Summary of progress. During the 5 year period of this research project, we have developed 
several new classes of inhibitors for HNE including isocoumarins (mechanism-based inhibitors), peptide 
cc-ketoesters (transition-state analogs), and peptide phosphonates (irreversible transition-state inhibitors). 
X-ray structural studies have been accomplished with 5 isocoumarin inhibitors bound to the active sites of 
PP elastase and trypsin, with 4 chloromethyl ketone inhibitors bound to the active site of FINE, and with 
one peptide a-ketoester inhibitor bound to the active site of PP elastase. The structural studies have led to 
a better understanding of the active site structures of these two important elastases and their mechanisms of 
inhibition. Several of the isocoumarin inhibitors developed have been studied with other physiologically 
important serine proteases and an influenza viral serine esterase. One of our inhibitors, 3,4- 
dichloroisocoumarin, is now commercially available from four companies for use as a general serine 
protease inhibitor. Isocoumarin and phosphonate inhibitors may prove to be valuable in other disease 
states related to serine protease activity and are currently being tested in animal models of sepsis and 
Alzheimer's disease. 
The various classes of elastase inhibitors discovered in my laboratory have been used extensively 
by pharmaceutical companies in the development of therapeutics for the treatment of emphysema. In 
particular, the chloromethyl ketone inhibitor MeO-Suc-Ala-Ala-Pro-Val-CH2C1 is used as the standard 
elastase inhibitor for the validation of new animal models of emphysema and as a standard elastase 
inhibitor to compare the effectiveness of newly developed inhibitors (Fletcher et al., 1990). 
Benzoxazinones and peptide a-ketoesters elastase inhibitors, discovered in my laboratory, have been 
chosen by Syntex Canada (Krantz et al., 1987; 1990) and Merrill Dow (Peet et al., 1990) for extensive 
development. Peptide sequences which we discovered to be potent elastase inhibitors have been translated 
into the sequences found in the potent trifluoromethyl ketone inhibitors of FIN elastase which are now 
undergoing development by ICI Americas as therapeutics (Trainor, 1987). The trifluoiomethyl ketone 
class of elastase inhibitors is probably the closest to reaching clinical use of any of the low molecular 
weight inhibitors available today and at least one derivative is undergoing phase I testing. 
Isocoumarin Mechanism-Based Inhibitors. Isocoumarins are mechanism -based (or 
suicide) heterocyclic serine proteases which are rich in possible masked reactive functional groups. Thus 
far, we have described isocoumarins which contain latent acid chloride or quinone imine methide 
functional groups. We have synthesized well over a hundred isocoumarin inhibitors, have published ca. 
13 papers and reviews which describe these inhibitors (see publication list at end of this section) and have 
still have not yet reported the majority of the compounds which we have synthesized. The recent 
completion of several x-ray structures of complexes of PPE inhibited by isocoumarins has yielded 
important insights into the binding modes of these inhibitors and we are working on two additional x-ray 














the study of an influenza viral esterase and a group of serine proteases isolated from natural killer cells 
(publication 4, 8, 13, 14). 
The inactivation mechanism of serine proteases by 3-alkoxy-7-amino-4-chloroisocoumarins (1) is 
shown below. The active site Ser-195 attacks the isocoumarin carbonyl group and opens the isocoumarin 
ring to form an acyl enzyme (2). This reaction unmasks a latent quinone imine methide functional group 
(3) which is formed by the elimination of HC1 from the acyl enzyme. This can react either with an enzyme 
nucleophile (His-57) to give an irreversibly inhibited enzyme structure (4) or with a solvent nucleophile to 
give a stable acyl enzyme (5). Partial reactivation by hydroxylamine with some inhibited derivatives 
suggests a partitioning between the two enzyme-inhibitor complexes (4 & 5) in solution with the 
nonreactivatable complex (4) containing an alkylated histidine residue. Both the 7-amino and 4-chloro 
groups are required for formation of a stable inactivated enzyme; isocoumarins which lack these features 
inhibit serine proteases, but deacylate fairly rapidly. 
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In addition to the kinetic evidence, the proposed inhibition mechanism is supported by x-ray 
crystallographic studies. Five enzyme-isocoumarin complexes have completed in collaboration with Ed 
Meyer (Texas A & M) and Wolfram Bode (Max Planck Institute, Munich) and are listed below. 
7-amino-4-chloro-3-methoxyisocoumarin & PPE - solvolysis product 5 with Nu = acetate -
(structure published, Meyer et al., 1987). 
4-chloro-3-ethoxy-7-guanidinoisocoumarin & PPE - acyl enzyme 2 with chlorine still present -
structure published in 1990, publication 2. 
4-chloro-3-ethoxy-7-guanidinoisocoumarin & trypsin - mixture of acyl enzyme 2 and the histidine 
alkylation product 4 - structure published in J. Am. Chem. Soc. 
7-amino-3-bromoethoxy-4-chloroisocoumarin & PPE - histidine alkylation product 4 - structure 
published. 
7-(Tos-Phe-NH)-4-chloro-3-ethoxyisocoumarin & PPE - histidine alkylation product 4 - structure 
complete and will be submitted soon. 
All the major products (2, 4, and 5) in the reaction scheme have been observed 
crystallographically with different isocoumarins. The observation of the doubly covalent bond histidine 
alkylation product 4 is the second time such a derivative has been observed with a serine protease. The 
first doubly covalently bound adduct was observed in a crystal structure of PPE inhibited by a 0-lactam 
inhibitor which was reported by a Merck group (Navia et al., 1987). The exact product formed in the 
inhibition reaction varies with both the enzyme and the isocoumarin inhibitor. Different inhibitors give 
variable ratios of hydroxylamine reactivatable acyl enzymes (2 or 5) or non-reactivatable alkylation 
products (4). The solvolysis product 5 is probably an artifact of that particular crystallographic 





protonated and less likely to undergo allcylation. Kinetic studies with a variety of inhibitors indicate that 
histidine alkylation is usually the favored product at neutral pH with both elastases and most of the 
isocoumarins studied. 
Isocoumarin Binding Modes. The binding modes of all five isocoumarins complexed to PPE 
and trypsin are remarkably different even though all are tethered to Ser-195 via an ester bond. The 
carbonyl group of the ester bond linking Ser-195 to the inhibitor is in the oxyanion hole of the serine 
protease in the 7-amino-4-chloro-3-methoxyisocoumarin complex with PPE, while it is twisted out of the 
oxyanion hole in the 7-guanidino structure. The twisting of the ester carbonyl group allows favorable 
hydrogen bonding between the 7-guanidino group and Thr-41 (6) and explains the stability of the complex 
toward deacylation. His-57 is either hydrogen bonded to the ester bond or is covalently linked with the 
inhibitor (4). 
Schematic drawings of the interactions observed in the PPE complexes with 4-chloro-3-ethoxy-7- 
guanidinoisocoumarin (6) and the 3-bromoethoxyisocoumarin (7) are shown below and a stereo drawing 
of 3 heterocyclic inhibitors superimposed in the active site of PPE is shown in Fig. 11 of publication 9. In 
the four PPE complexes, the 3-alkoxy group of the isocoumarin is either in the S 1 pocket or lying nearby. 
However in the complex of trypsin with 4-chloro-3-ethoxy-7-guanidinoisocoumarin, the 7-guanidino 
group of the isocoumarin is inserted into the Si pocket of trypsin to interact with Asp-189 in trypsin's 
binding pocket, while the 3-alkoxy group points toward the S' subsites of the enzyme. This orientation is 
almost 180° from the orientation found in the complex of the same compound with PPE (6). Thus a 
significantly different binding geometry has been observed for the first time when the same inhibitor is 
examined with different two serine proteases. It is clear that we don't know all the rules for predicting the 
preferred binding conformation of a small molecule inhibitor to the active site of a serine protease. 
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Molecular Modeling and Inhibitor Design. Although it is not yet possible to predict the 
binding mode of a new isocoumarin inhibitor to elastase, molecular modeling with x-ray crystal structures 
is extremely useful for improving that inhibitor and for interpreting inhibition kinetic data obtained with 
related inhibitor structures. For example, molecular modeling of the 7-guanidinoiso: -..oumarin PPE 
complex 6 suggested that the addition of a small alkyl group (t-butyl) to the guanidino group might 
increase affinity to the enzyme due to the presence of a small hydrophobic pocket near the terminal 
nitrogen of guanidino group and above Thr-41. Therefore, we synthesized a series of 7-alkyl-NH-CO-
NH- derivatives of 4-chloro-3-ethoxyisocoumarin. These ureas were chosen for synthesis due to the 
difficulty of synthesizing alkyl guanidino derivatives. Replacement of the 7-guanidino group by a urea 
functional group resulted in almost no loss of inhibitory potency (see following table). As predicted, the t-
butyl-NH-CO-NH- derivative was the most effective PPE inhibitor and had a second order inhibition rate 
kobsd/[I] which was 3.5 fold higher than the parent inhibitor. Indeed, the compounds developed from the 
modeling are among the best irreversible inhibitors reported thus far for PPE (work is described in 
publication 2). In order to confirm the binding mode predicted from molecular modeling, the Meyer group 
is currently determining the structure of PPE inhibited by 7-(t-Bu-HN-CO-NH)-EtOIC. 
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7-(H2N-C(=NH2+)-NH)-EtOIC 	 2300M-1 s-1 
7-(H2N-CO-NH)-EtOIC 2200 
7-(Me-HN-CO-NH)-EtOIC 	 1400 
7-(Et-HN-CO-NH)-EtOIC 1700 	 EtOIC = 
7-(i-Pr-HN-CO-NH)-EtOIC 	 4900 4-chloro- 
7-(t-Bu-HN-CO-NH)-EtOIC 8100 	 3-ethoxy 
7-(Ph-HN-CO-NH)-EtOIC 	 4200 isocoumarin 
One we realized that the 3-alkoxy group of the isocoumarin was fitting into the S1 pocket of 
elastase, we synthesized a number of derivatives with 3-alkoxy groups of varying length. With HNE, we 
found the following inhibition constants: MeO, 10,000; EtO, 9,400; PrO, 54,000; and bromoethoxy, 
200,000. Clearly HNE prefers the long alkoxy groups. The structure determination of the complex of the 
3-bromoethoxyisocoumarin (7) with PPE has allowed us to interpret our kinetic data with PPE (see 
following table, all the bromoethoxy derivatives are ca. 100 fold better with HNE, data not shown). First 
it is clear that the bromopropoxy derivatives with a slightly long alkoxy group are over 100 fold poorer 
inhibitors of PPE and HNE. All of the derivatives in which a hydrophobic group is placed on the 7-amino 
group are 3-7 fold better inhibitors than the parent with the exception of the phenyl urea derivative which is 
much poorer. The 7-amino group of the isocoumarin points toward the S' subsites of PPE and FINE and 
we predict that the hydrophobic groups in the extended inhibitors are interacting with the S2' subsite (Leu-
143, Leu-151, Thr-41 in PPE). The phenyl urea derivative is probably so rigid, that the 7-substituent 






7-(R-(C6H5)(CH3)CH-NH-CO-NH) 9,900  





Human Neutrophil Elastase Inhibitors. Unfortunately, no crystal structures of an 
isocoumarin bound to HNE is available or likely to become available. Wolfram Bode and the Merck group 
have tried extensively to crystallize complexes of HNE bound to small molecule inhibitors. Up to the 
present, the smallest inhibitor which has yielded crystals with HNE is a tetrapeptide such as Me0-Suc-Ala-
Ala-Pro-Val-CH2C1. However, the crystal structures obtained with PPE have been invaluable for 
modeling with HNE. The active site structures of PPE and HNE have many features in common (see the 
review, publication 9) and so we feel quite comfortable using the PPE crystal structures for modeling with 
HNE. For example, the complex of the 7-Tos-Phe derivative of 4-chloro-3-ethoxyisocoumarin has been 
determined and has the 3-alkoxy group in the S l pocket and the Tos-Phe group interacting with the S' 
subsites of PPE (shown below left). Representative inhibition rates with FINE are shown below (right). 
The derivatives shown all have a 3-propoxy group instead of the 3-ethoxy group shown in the crystal 
structure since we demonstrate that HNE preferred to an alkoxy group with one more methylene group. 
Clearly, most of the rates are so fast that the rate constants should be considered to be lower limits. 
The active site of HNE is much more hydrophobic than that of PPE. Two significant changes are: 
Thr-41 in PPE is replaced in HNE by Phe-41 and Gln-192 is changed to Phe-192. Molecular modeling 
with HNE indicates that the Tos-Phe group is interacting with the S' subsites consisting of the side chains 
of Phe-41, Leu-35, and Leu-143. Clearly all the hydrophobic 7-substituents are making favorable 
contacts with HNE and as a result are extremely potent inhibitors. 
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Dichloroisocoumarin. We should also mention 3,4-dichloroisocoumarin which we reported as 
a general serine protease inhibitor in 1985 (publication 29) HLE and PPE are both inhibited effectively by 
3,4-dichloroisocoumarin with kobsd/[1]  values of 8900 and 2500 M-1  s-1 respectively. Although the 
elastases are most effectively inhibited, dichloroisocoumarin is a general serine protease inhibitor and 
reacts with all serine proteases which have been investigated thus far. It is now commercially available 
from four companies and is becoming widely used for diagnosing new serine proteases since it is more 
reactive than PMSF and less hazardous than DFP. It addition it has also been invaluable to show that 
serine proteases are involved in natural killer cell and cytotoxic T lymphocyte granule mediated killing of 
targeted cells (publications 4, 13, 14). I expect to see this inhibitor increasingly used by other 
investigators in the future. 
Peptide Phosphonate Inhibitors. Peptidyl derivatives of a-aminoalkylphosphonate diphenyl 
ester are effective and specific inhibitors of serine proteases at low concentrations. These inhibitors are 
chemically stable, relatively easy to synthesize, and do not react with acetylcholinesterase. Previously 
synthesized phosphonate inhibitors of serine proteases include phosphonyl fluorides or phosphonamides 
which are unstable in solution and/or reactive toward acetylcholinesterase. Our phosphonate diphenyl 
esters form very stable derivatives with serine proteases due to the resemblance between the inhibition 
product (phosphonyl derivative shown below) and the tetrahedral intermediate involved in peptide bond 
hydrolysis. Our phosphonates are stable for at least 3 days in human plasma and the inhibited enzyme has 
a half-life for reactivation of 10 hrs in the case of chymotrypsin and >3 days in the case of the elastases. 
Although phosphonates are not as reactive as isocoumarins, we believe that they have considerable utility 
as therapeutic agents due their high stability and specificity. 
Aminoalkylphosphonate diphenyl esters are very specific for the target serine protease and the data 
suggests that good interactions with the S1 pocket of the target serine protease are necessary before 
nucleophilic substitution on phosphorus atom occurs to give a stable phosphonyl derivative. For example, 
Suc-Val-Pro-PheP(OPh)2 reacts with chymotrypsin (cobsen = 41,00°, M-1 s -1 ) and does not react with 
elastases. Boc-Val-Pro-ValP(OPh)2 reacts with HNE (27,000 m-is-1)  and PPE (11,000 M- ls-1 ) and 
does not react with chymotrypsin. The longer peptides with a C-terminal phosphonate related to 
phenylalanine are also inhibitors for other chymotrypsin-like 












The inhibition reaction is stereospecific since 31 P NMR studies have shown than only one of the 
two stereoisomers of Suc-Val-Pro-PheP(OPh)2 reacts with chymotrypsin with a rate constant which is 
higher than (146,000 M -1 s-1 ) the mixture. The 31 P NMR of chymotrypsin inhibited by this peptide 
shows one broad signal at 25.98 ppm corresponding to the Ser-195 phosphonate ester which is consistent 
with the product structure shown above. 
Peptide a-Ketoester Transition-State Inhibitors. A variety of transition-state inhibitors 
for elastase are currently available including peptide aldehydes, peptide boronic acids, and peptide 
trifluoromethyl ketones. During the course of this research, we developed novel peptide a-ketoesters as 
another type of transition-state inhibitor for elastases. This class of inhibitors was based on the refined x-
ray crystal structure of the complex formed between bovine trypsin and the ketoacid inhibitor 4- 
amidinophenylpyruvate (APPA), a potent trypsin inhibitor (Walter and Bode, 1983). In the x-ray 
structure, the amidinophenyl group is located in the primary specificity pocket of trypsin and the active site 
serine has added to the 2-carbonyl group in APPA. The oxyanion is stabilized by hydrogen bonding with 
groups in the oxyanion hole of trypsin. A unique feature of this structure is the hydrogen bonding 
observed between the carboxylate oxygen and the serine oxygen and the NH of histidine-57. We expected 
that the negative charge on the carboxylate would significantly contribute to the binding energy of a-
ketoacids. 
We designed and synthesized a number of peptide derivatives of various a-ketoacids and a-
ketoesters derived from several different amino acids. Some of our kinetic results are shown in the 
following table where ICI values are report in p.M in 0.1 M Hepes, pH 7.5, 0.5 M NaC1, 9.0-9.8% 
Me2S0 at 25°C (Ala-CO2Et = -NHCH(CH3)CO-CO2Et; Abu = 2-aminobutanoic acid). Surprisingly, the 
a-ketoesters are much better inhibitors than the corresponding acids which indicates that additional 
interactions with the Si' subsite and hydrogen bonding of the ester oxygen with the histidine N-H can 
result in significant binding energy in the case of elastase. The best inhibitors, Z-Ala-Ala-DL-Abu-
COOEt, the corresponding benzyl ester, and Z-Ala-Ala-Ala-DL-Ala-COOEt, had KI values in the 
submicromolar range (publication 28). Importantly, MeO-Suc-Val-Pro-Phe-COOMe is one of the most 
potent reversible cathepsin G inhibitors known. 
Inhibitor 	 HLE 	PPE 	 Cat G 
Bz-DL-Ala-COOEt 	640 JIM 590 




Me0-Suc-Val-Pro-DL-Phe-COOMe 	 1.1 
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Key Personnel (August 1, 1989 to March 31, 1991) 
A crystal structure of one a-ketoester bound into the active site of PPE has been completed in the 
Meyer laboratory and a schematic drawing of the interactions observed is shown below. The Ser-195 
oxygen has added to the carbonyl group of the ketoester to form a tetrahedral intermediate which is 
stabilized by interactions with the oxyanion hole. This structure resembles the tetrahedral intermediate 
involved in peptide bond hydrolysis and proves that a-ketoesters are transition-state analogs. His-57 is 
hydrogen bonded to the carbonyl group of the ester functional group, the peptide backbone on a section of 
PPE's backbone hydrogen bonds to the inhibitor to form a p-sheet, and the benzyl ester is directed toward 
the S' subsites. It appears likely that the potency of this class of inhibitor could be substantially improved 
if the structure was extended to allow for more interactions with the S' subsites. 
James C. Powers 	 PI 	 8% 
Chih-Min Kam Research Scientist 	 25% 
Masaru Yamamoto 	 Graduate Student 100% 
Andrea Lauro 	 Graduate Student 	 42% 
Charles Houck Graduate Student 100% 
Margaret Robinson 	 Graduate Student 	 100% 
John Kerrigan 	 Graduate Student 100% 
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York. 
21. "Inhibitors of Metalloproteases", Powers, J. C., and Harper, J. W. (1986) Proteinase Inhibitors 
(Barrett, A. J., and Salvensen, G. S., Eds.) pp 219-298, Elsevier Science Publishers, Amsterdam/New 
York. 
22. "Serine Proteases of Leukocyte and Mast Cell Origin. Substrate Specificity and Inhibition of 
Elastase, Chymases and Tryptases", Powers, J. C. (1986) Therapeutic Control of Inflammatory Diseases. 
New Approaches to Antirheumatic Drugs. Adv. in Inflammation Research 11, 145-157. 
23. "Reaction of Serine Proteases with Substituted 3-Alkoxy-4-chloroisocoumarins and 3-Alkoxy-7- 
amino-4-chloroisocoumarins: New Reactive Mechanism-Based Inhibitors, " J.W. Harper, and J.C. 
Powers (1985) Biochemistry 24, 7200-7213. 
24. "Mammalian Chymotrypsin-like Enzymes. Comparative Reactivities of Rat Mast Cell Proteases, 
Human and Dog Skin Chymases, and Human Cathepsin G with Peptide 4-Nitroanilide Substrates and 
with Peptide Chloromethyl Ketone and Sulfonyl Fluoride Inhibitors", Powers, J. C., Tanaka, T., Harper, 
J. W., Minematsu, Y., Barker, L., Lincoln, D., Crumley, K. V., Fraki, J. E., Schechter, N. M., 
Lazarus, G. G., Nakajima, K., Nakashino, K., Neurath, H., and Woodbury, R. G. (1985) Biochemistry 
24, 2048-2058. 
25. "Human Leukocyte Cathepsin G. Subsite Mapping with 4-Nitroanilides, Chemical Modification, 
and Effect of Possible Cofactors", T. Tanaka, Y. Minematsu, C.F. Reilly, J. Travis, and J.C. Powers 
(1985) Biochemistry 24, 2040-2047. 
26. "Inhibition of Human Leukocyte Elastase, Cathepsin G, Chymotrypsin A, and Porcine Pancreatic 
Elastase with Substituted Isobenzofuranones and Benzopyrandiones", K. Hemmi, J. W. Harper, and J. 
C. Powers (1985) Biochemistry 24, 1841-1848. 
27. "Reaction of Serine Proteases with Substituted Isocoumarins: Discovery of 3,4- 
Dichloroisocoumarin, a New General Mechanism Based Serine Protease Inhibitor", J. W. Harper, K. 
Hemmi, and J.C. Powers (1985) Biochemistry 24, 1831-1841. 
28. "Inhibition of Human Leukocyte Elastase, Porcine Pancreatic Elastase and Cathepsin G by Peptide 
Ketones", H. Hori, A. Yasutake, Y. Minematsu, and J.C. Powers (1985) Peptides: Synthesis-Structure-
Function. Proceeding of the Ninth American Peptide Symposium (C. M. Deber, V. J. Hruby, and K. D. 
Kopple, Eds.) pp 819-822, Pierce Chem. Co., II. 
Patents 
"Thioester Inhibitors of Serine Proteases", J. C. Powers (1986) U.S. Patent 4,585,793. 
"Heterocyclic Inhibitors of Serine Proteases", J. C. Powers and J. W. Harper (1986) U.S. Patent 
4,596,822. 
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"Aryl Sulfonyl Fluoride Compounds", J. C. Powers (1987) U. S. Patent 4,659,855. 
"Aryl Sulfonyl Fluoride Inhibitors of Elastase and Chymotrypsin-like Enzymes", J. C. Powers 
(1988) U. S. Patent 4,725,545. 
"Heterocyclic Inhibitors of Serine Proteases, J. C. Powers (1989) U. S. Patent 4,847,202. 
Patents Pending 
"Heterocyclic Inhibitors of Serine Proteases, J. C. Powers (1989) continuation in part filed July 
1988. 
"Substituted Isocoumarins," J. C. Powers, C.-M. Kam, J. Oleksyszyn, J. A. Glinski, and M. A. 
Hernandez (1990) continuation in part filed April 1990. 
"Substituted Isocoumarins as Serine Protease Inhibitors, and Anti-inflammatory Agents," J. C. 
Powers, C.-M. Kam, J. Oleksyszyn, J. A. Glinski, and M. A. Hernandez (1990) continuation in part 
filed April 1990. 
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structures, investigate the mechanisms of elastase inhibition, determine the structure of inhibitor complexes, 
and to understand the basic underlying mechanism by which HNE inhibitors work in animals. 
HNE Inhibitors in Animal Models. The literature on in vivo testing of elastase inhibitors as 
preventatives of elastase-induced emphysema in laboratory animals has been reviewed by the Boston U. group 
(Snider et al., 1986), and they have published a number of papers in this area (Stone et al., 1981; 1990a; 
1990b; Snider et al., 1985; Lucey et al., 1982; 1986; 1989; 1990). A wide variety of structures including 
peptide chloromethyl ketone inhibitors, transition state inhibitors, and natural and recombinant protein 
inhibitors have been shown to be effective in animal models of emphysema. In addition, al-PI replacement 
therapy is currently undergoing trials at several centers in the U. S. for the treatment of PiZZ patients who are 
deficient in the inhibitor. The natural inhibitor has a 12-16 hr lifetime in plasma and must be replenished by 
periodic injections. Thus far, it is expensive and available only in small quantities. 
C . PROGRESS REPORT 
Specific Aims. The major specific aim of our previous application was the development of a 
synthetic elastase inhibitor which would be useful for the treatment of human emphysema. A variety of 
inhibitor structures were proposed including heterocyclic mechanism-based inhibitors and peptide transition 
state analogs. We proposed to test the specificity of all new inhibitors with other PMN proteases such as 
human leukocyte cathepsin G. A secondary goal of the research was the extension of potent inhibitor 
structures to other serine proteases. We suggested that inhibitor studies would lead to a better understanding of 
the active site structures of the serine proteases involved in connective tissue turnover, might produce clinically 
useful drugs for the treatment of emphysema and related diseases, would stimulate the research of medicinal 
chemists in pharmaceutical companies, and will provide new tools for the in vivo and in vitro study of the role 
of neutrophil and mast cell proteases in a variety of physiological processes. 
Summary of progress. During the 5 year period of this research project, we have developed 
several new classes of inhibitors for HNE including isocoumarins (mechanism-based inhibitors), peptide a-
ketoesters (transition-state analogs), and peptide phosphonates (irreversible transition-state inhibitors). X-ray 
structural studies have been accomplished with 5 isocoumarin inhibitors bound to the active sites of PP elastase 
and trypsin, with 4 chloromethyl ketone inhibitors bound to the active site of HNE, and with one peptide a-
ketoester inhibitor bound to the active site of PP elastase. The structural studies have led to a better 
understanding of the active site structures of these two important elastases and their mechanisms of inhibition. 
Several of the isocoumarin inhibitors developed have been studied with other physiologically important serine 
proteases and an influenza viral serine esterase. One of our inhibitors, 3,4-dichloroisocoumarin, is now 
commercially available from four companies for use as a general serine protease inhibitor. Isocoumarin and 
phosphonate inhibitors may prove to be valuable in other disease states related to serine protease activity and 
are currently being tested in animal models of sepsis and Alzheimer's disease. 
The various classes of elastase inhibitors discovered in my laboratory have been used extensively by 
pharmaceutical companies in the development of therapeutics for the treatment of emphysema. In particular, 
the chloromethyl ketone inhibitor Me0-Suc-Ala-Ala-Pro-Val-CH2C1 is used as the standard elastase inhibitor 
for the validation of new animal models of emphysema and as a standard elastase inhibitor to compare the 
effectiveness of newly developed inhibitors (Fletcher et al., 1990). Benzoxazinones and peptide a-ketoesters 
elastase inhibitors, discovered in my laboratory, have been chosen by Syntex Canada (Krantz et al., 1987; 
1990) and Merrill Dow (Peet et al., 1990) for extensive development. Peptide sequences which we discovered 
to be potent elastase inhibitors have been translated into the sequences found in the potent trifluoromethyl 
ketone inhibitors of }IN elastase which are now undergoing development by ICI Americas as therapeutics 
(Trainor, 1987). The trifluoromethyl ketone class of elastase inhibitors is probably the closest to reaching 
clinical use of any of the low molecular weight inhibitors available today and at least one derivative is 
undergoing phase I testing. 
Isocoumarin Mechanism -Based Inhibitors. Isocoumarins are mechanism-based (or suicide) 
heterocyclic serine proteases which are rich in possible masked reactive functional groups. Thus far, we have 
described isocoumarins which contain latent acid chloride or quinone imine methide functional groups. We 
have synthesized well over a hundred isocoumarin inhibitors, have published ca. 13 papers and reviews which 
describe these inhibitors (see publication list at end of this section) and have still have not yet reported the 
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complexes of PPE inhibited by isocoumarins has yielded important insights into the binding modes of these 
inhibitors and we are working on two additional x-ray papers and a J. Med. Chem. paper. In addition to 
elastase, the isocoumarins have proved to be useful in the study of an influenza viral esterase and a group of 
serine proteases isolated from natural killer cells (publication 4, 8, 13, 14). 
The inactivation mechanism of serine proteases by 3-alkoxy-7-amino-4-chloroisocoumarins (1) is 
shown below. The active site Ser-195 attacks the isocoumarin carbonyl group and opens the isocoumarin ring 
to form an acyl enzyme (2). This reaction unmasks a latent quinone imine methide functional group (3) which 
is formed by the elimination of HC1 from the acyl enzyme. This can react either with an enzyme nucleophile 
(His-57) to give an irreversibly inhibited enzyme structure (4) or with a solvent nucleophile to give a stable acyl 
enzyme (5). Partial reactivation by hydroxylamine with some inhibited derivatives suggests a partitioning 
between the two enzyme-inhibitor complexes (4 & 5) in solution with the nonreactivatable complex (4) 
containing an alkylated histidine residue. Both the 7-amino and 4-chloro groups are required for formation of a 
stable inactivated enzyme; isocoumarins which lack these features inhibit serine proteases, but deacylate fairly 
rapidly. 
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In addition to the kinetic evidence, the proposed inhibition mechanism is supported by x-ray 
crystallographic studies. Five enzyme-isocoumarin complexes have completed in collaboration with Ed Meyer 
(Texas A & M) and Wolfram Bode (Max Planck Institute, Munich) and are listed below. 
7-amino-4-chloro-3-methoxyisocoumarin & PPE - solvolysis product 5 with Nu = acetate - (structure 
published, Meyer et al., 1987). 
4-chloro-3-ethoxy-7-guanidinoisocournarin & PPE - acyl enzyme 2 with chlorine still present -
structure published in 1990, publication 2. 
4-chloro-3-ethoxy -7-guanidinoisocoumarin & trypsin - mixture of acyl enzyme 2 and the histidine 
alkylation product 4 - manuscript accepted by J. Am. Chem. Soc. 
7-amino-3-bromoethoxy-4-chloroisocoumarin & PPE - histidine alkylation product 4 - structure 
completed and manuscript will be submitted in Aug. 
7-(Tos-Phe-NH)-4-chloro-3-ethoxyisocoumarin & PPE - histidine alkylation product 4 - structure 
being refined. 
All the major products (2, 4, and 5) in the reaction scheme have been observed crystallographically 
with different isocoumarins. The observation of the doubly covalent bond histidine alkylation product 4 is the 
second time such a derivative has been observed with a serine protease. The first doubly covalently bound 
adduct was observed in a crystal structure of PPE inhibited by a 13-lactam inhibitor which was reported by a 
Merck group (Navia et al., 1987). The exact product formed in the inhibition reaction varies with both the 
enzyme and the isocoumarin inhibitor. Different inhibitors give variable ratios of hydroxylamine reactivatable 
acyl enzymes (2 or 5) or non-reactivatable alkylation products (4). The solvolysis product 5 is probably an 
artifact of that particular crystallographic experiment which was carried out in an acetate buffer at pH 5.0, a pH 
where the His-57 would be protonated and less likely to undergo allcylation. Kinetic studies with a variety of 
inhibitors indicate that histidine allcylation is usually the favored product at neutral pH with both elastases and 
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Isocoumarin Binding Modes. The binding modes of all five isocoumarins complexed to PPE and 
trypsin are remarkably different even though all are tethered to Ser-195 via an ester bond. The carbonyl group 
of the ester bond linking Ser-195 to the inhibitor is in the oxyanion hole of the serine protease in the 7-amino-4 
chloro-3-methoxyisocournarin complex with PPE, while it is twisted out of the oxyanion hole in the 7-
guanidino structure. The twisting of the ester carbonyl group allows favorable hydrogen bonding between the 
7-guanidino group and Thr-41 (6) and explains the stability of the complex toward deacylation. His-57 is 
either hydrogen bonded to the ester bond or is covalently linked with the inhibitor (4). 
Schematic drawings of the interactions observed in the PPE complexes with 4-chloro-3-ethoxy-7- 
guaniclinoisocournarin (6) and the 3-bromoethoxyisocournarin (7) are shown below and a stereo drawing of 3 
heterocyclic inhibitors superimposed in the active site of PPE is shown in Fig. 11 of publication 9. In the four 
PPE complexes, the 3-alkoxy group of the isocoumarin is either in the Si pocket or lying nearby. However in 
the complex of trypsin with 4-chloro-3-ethoxy-7-guanidinoisocoumarin, the 7-guanidino group of the 
isocoumarin is inserted into the Si pocket of trypsin to interact with Asp-189 in trypsin's binding pocket, while 
the 3-alkoxy group points toward the S' subsites of the enzyme. This orientation is almost 180° from the 
orientation found in the complex of the same compound with PPE (6). Thus a significantly different binding 
geometry has been observed for the first time when the same inhibitor is examined with different two serine 
proteases. It is clear that we don't know all the rules for predicting the preferred binding conformation of a 








Molecular Modeling and Inhibitor Design. Although it is not yet possible to predict the binding 
mode of a new isocoumarin inhibitor to elastase, molecular modeling with x-ray crystal structures is extremely 
useful for improving that inhibitor and for interpreting inhibition kinetic data obtained with related inhibitor 
structures. For example, molecular modeling of the 7-guanidinoisocoumarin PPE complex 6 suggested that 
the addition of a small alkyl group (t-butyl) to the guanidino group might increase affinity to the enzyme due to 
the presence of a small hydrophobic pocket near the terminal nitrogen of guanidino group and above Thr-41. 
Therefore, we synthesized a series of 7-alkyl-NH-CO-NH- derivatives of 4-chloro-3-ethoxyisocoumarin. 
These ureas were chosen for synthesis due to the difficulty of synthesizing allcyl guanidino derivatives. 
Replacement of the 7-guanidino group by a urea functional group resulted in almost no loss of inhibitory 
potency (see following table). As predicted, the t-butyl-NH-CO-NH- derivative was the most effective PPE 
inhibitor and had a second order inhibition rate lcobsd/M which was 3.5 fold higher than the parent inhibitor. 
Indeed, the compounds developed from the modeling are among the best irreversible inhibitors reported thus 
far for PPE (work is described in publication 2). In order to confirm the binding mode predicted from 
molecular modeling, the Meyer group is currently determining the structure of PPE inhibited by 7-(t-Bu-HN-
CO-NH)-EtOIC. 
	
7-(H2N-C(=NH2+)-NH)-EtOIC 	 2300 M- ls-1 
7-(H2N-CO-NH)-EtOIC 2200 
7-(Me-HN-CO-NH)-EtOIC 	 1400 
7-(Et-HN-CO-NH)-EtOIC 1700 	 EtOIC = 
7-(i-Pr-HN-CO-N11)-EtOIC 	 4900 4-chloro- 
7-(t-B u-HN-CO-NH)-EtOIC 8100 	 3-ethoxy 
7-(Ph-HN-CO-NH)-EtOIC 	 4200 isocoumarin 
One we realized that the 3-alkoxy group of the isocoumarin was fitting into the Si pocket of elastase, 
we synthesized a number of derivatives with 3-allcoxy groups of varying length. With HNE, we found the 
following inhibition constants: MeO, 10,000; EtO, 9,400; PrO, 54,000; and bromoethoxy, 200,000. Clearly 
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bromoethoxyisocoumarin (7) with PPE has allowed us to interpret our kinetic data with PPE (see following 
table, all the bromoethoxy derivatives are ca. 100 fold better with HNE, data not shown). First it is clear that 
the bromopropoxy derivatives with a slightly long alkoxy group are over 100 fold poorer inhibitors of PPE and 
HNE. All of the derivatives in which a hydrophobic group is placed on the 7-amino group are 3-7 fold better 
inhibitors than the parent with the exception of the phenyl urea derivative which is much poorer. The 7-amino 
group of the isocoumarin points toward the S' subsites of PPE and HNE and we predict that the hydrophobic 
groups in the extended inhibitors are interacting with the S2' subsite (Leu-143, Leu-151, Thr-41 in PPE). The 
phenyl urea derivative is probably so rigid, that the 7-substituent can't twist and adopt a favorable conformation 
in the active site. 
7-substituted-4-chloro-3-(2-bromoethoxy)isocoumarin 
	
7-NH2 	 1,000 	M-1 54 
7-(t-Bu-NH-CO-NH) 6,600 
7-(Ph-NH-CO-NH) 	 36 
7-(Ph-CH2-NH-CO-NH) 3,010 
7-(R-(C6H5)(CH3)CH-NH-CO-NH) 	 9,900 
7-(Ph-CH2-CO-NH) 4,950 
7-substituted-4-chloro-3-(3-bromopropoxy)isocoumarin 
7-NH2 	 10 
7-(Ph-CH2-NH-CO-NH) 13 
7-(Ph-CH2-CO-NH) 	 28 
Human Neutrophil Elastase Inhibitors. Unfortunately, no crystal structures of an isocoumarin 
bound to HNE is available or likely to become available. Wolfram Bode and the Merck group have tried 
extensively to crystallize complexes of HNE bound to small molecule inhibitors. Up to the present, the 
smallest inhibitor which has yielded crystals with HNE is a tetrapeptide such as Me0-Suc-Ala-Ala-Pro-Val-
CH2C1. However, the crystal structures obtained with PPE have been invaluable for modeling with HNE. 
The active site structures of PPE and HNE have many features in common (see the review, publication 9) and 
so we feel quite comfortable using the PPE crystal structures for modeling with HNE. For example, the 
complex of the 7-Tos-Phe derivative of 4-chloro-3-ethoxyisocoumarin has been determined and has the 3-
alkoxy group in the S1 pocket and the Tos-Phe group interacting with the S' subsites of PPE (shown below 
left). Representative inhibition rates with HNE are shown below (right). The derivatives shown all have a 3- 
propoxy group instead of the 3-ethoxy group shown in the crystal structure since we demonstrate that HNE 
preferred to an alkoxy group with one more methylene group. Clearly, most of the rates are so fast that the rate 
constants should be considered to be lower limits. 
CH3CO 	>190,000 
33,400 M- ls-1 Tos-Phe 
Ser-195 	 >124,000 0. CH3CH2CH2CO  (CH3)6CHCH2C0 	>220,000 
•1 	




















S. subsites PhCH2NHCS 
>166,000 
The active site of HNE is much more hydrophobic than that of PPE. Two significant changes are: Thr-
41 in PPE is replaced in HNE by Phe-41 and Gln-192 is changed to Phe-192. Molecular modeling with HNE 
indicates that the Tos-Phe group is interacting with the S' subsites consisting of the side chains of Phe-41, Leu-
35, and Leu-143. Clearly all the hydrophobic 7-substituents are making favorable contacts with HNE and as a 
result are extremely potent inhibitors. 
Dichloroisocoumarin. We should also mention 3,4-dichloroisocoumarin which we reported as a 
general serine protease inhibitor in 1985 (publication 29). HLE and PPE are both inhibited effectively by 3,4-
dichloroisocoumarin with kobsdirn  values of 8900 and 2500 M - ls-1 respectively. Although the elastases are 
most effectively inhibited, dichloroisocoumarin is a general serine protease inhibitor and reacts with all serine 
proteases which have been investigated thus far. It is now commercially available from four companies and is 
becoming widely used for diagnosing new serine proteases since it is more reactive than PMSF and less 
hazardous than DFP. It addition it has also been invaluable to show that serine proteases are involved in 
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natural killer cell and cytotoxic T lymphocyte granule mediated killing of targeted cells (publications 4, 13, 14). 
I expect to see this inhibitor increasingly used by other investigators in the future. 
Peptide Phosphonate Inhibitors. Peptidyl derivatives of a-aminoalkylphosphonate diphenyl ester 
are effective and specific inhibitors of serine proteases at low concentrations. These inhibitors are chemically 
stable, relatively easy to synthesize, and do not react with acetylcholinesterase. Previously synthesized 
phosphonate inhibitors of serine proteases include phosphonyl fluorides or phosphonamides which are 
unstable in solution and/or reactive toward acetylcholinesterase. Our phosphonate diphenyl esters form very 
stable derivatives with serine proteases due to the resemblance between the inhibition product (phosphonyl 
derivative shown below) and the tetrahedral intermediate involved in peptide bond hydrolysis. Our 
phosphonates are stable for at least 3 days in human plasma and the inhibited enzyme has a half-life for 
reactivation of 10 hrs in the case of chymotrypsin and >3 days in the case of the elastases. Although 
phosphonates are not as reactive as isocoumarins, we believe that they have considerable utility as therapeutic 
agents due their high stability and specificity. 
Active Site 	 Active Site 
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Aminoalkylphosphonate diphenyl esters are very specific for the target serine protease and the data 
suggests that good interactions with the S1 pocket of the target serine protease are necessary before 
nucleophilic substitution on phosphorus atom occurs to give a stable phosphonxl derivative. For example, 
Suc-Val-Pro-PheP(OPh)2 reacts with chymotrypsin (cobsd/[ 1] = 44, ,000, 	M-l s-1 ) and does not react with 
elastases. Boc-Val-Pro-Valr(OPh)2 reacts with HNE (27,000 NI' Is - I) and PPE (11,000 M-1 0) and does 
not react with chymotrypsin. The longer peptides with a C-terminal phosphonate related to phenylalanine are 
also inhibitors for other chymotrypsin-like enzymes such as rat mast cell protease II and human cathepsin G. 
ChyT 	PPE 	IMTE 
Me0-Suc-Ala-Ala-Pro-NvaP(OPh)2 50 4200 380 
Me0-Suc-Ala-Ala-Ala-Va1P(OPh)2 15 2800 1500 
Me0-Suc-Ala-Ala-Ala-PheP(OPh)2 2,000 NI NI 
Me0-Suc-Ala-Ala-Pro-N/ alP(OPh)2 21 7,100 7,100 
Me0-Suc-Ala-Ala-Pro-LeuP(OPh)2 1,500 740 140 
Me0-Suc-Ala-Ala-Pro-PheP(OPh)2 11,000 NI NI 
Me0-Suc-Ala-Ala-Pro-MetP(OPh)2 570 44 53 
Me0-Suc-Ala-Ala-Pro-Met(0)P(OPh)2 15 1.6 1.6 
Boc-Val-Pro-Va1P(OPh)2 NI 11,000 27,000 
Z-Phe-Pro-PheP(OPh)2 17,000 NI NI 
Suc-Val-Pro-PheP(OPh)2 44,000 NI NI 
The inhibition reaction is stereospecific since 31P NMR studies have shown than only one of the two 
stereoisomers of Suc-Val-Pro-PheP(QPh)2 reacts with chymotrypsin with a rate constant which is higher than 
(146,000 M-1 s-1 ) the mixture. The ilP NMR of chymotrypsin inhibited by this peptide shows one broad 
signal at 25.98 ppm corresponding to the Ser-195 phosphonate ester which is consistent with the product 
structure shown above. 
Peptide a-Ketoester Transition-State Inhibitors. A variety of transition-state inhibitors for 
elastase are currently available including peptide aldehydes, peptide boronic acids, and peptide trifluoromethyl 
ketones. During the course of this research, we developed novel peptide a-ketoesters as another type of 
transition-state inhibitor for elastases. This class of inhibitors was based on the refined x-ray crystal structure 
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of the complex formed between bovine trypsin and the ketoacid inhibitor 4-amidinophenylpyruvate (APPA), a 
potent trypsin inhibitor (Walter and Bode, 1983). In the x-ray structure, the amidinophenyl group is located in 
the primary specificity pocket of trypsin and the active site serine has added to the 2-carbonyl group in APPA. 
The oxyanion is stabilized by hydrogen bonding with groups in the oxyanion hole of trypsin. A unique feature 
of this structure is the hydrogen bonding observed between the carboxylate oxygen and the serine oxygen and 
the NH of histidine-57. We expected that the negative charge on the carboxylate would significantly contribute 
to the binding energy of a-ketoacids. 
We designed and synthesized a number of peptide derivatives of various a-ketoacids and a-ketoesters 
derived from several different amino acids. Some of our kinetic results are shown in the following table where 
KI values are report in pM in 0.1 M Hepes, pH 7.5, 0.5 M NaC1, 9.0-9.8% Me2S0 at 25°C (Ala-CO2Et = - 
NHCH(CH3)CO-0O2Et; Abu = 2-aminobutanoic acid). Surprisingly, the a-ketoesters are much better 
inhibitors than the corresponding acids which indicates that additional interactions with the Si' subsite and 
hydrogen bonding of the ester oxygen with the histidine N-H can result in significant binding energy in the 
case of elastase. The best inhibitors, Z-Ala-Ala-DL-Abu-COOEt, the corresponding benzyl ester, and Z-Ala-
Ala-Ala-DL-Ala-COOEt, had KI values in the submicromolar range (publication 28). Importantly, Me0-Suc-
Val-Pro-Phe-COOMe is one of the most potent reversible cathepsin G inhibitors known. 
Inhibitor 	 HLE 	PPE 
	
Bz-DL-Ala-COOEt 	640 p.M 590 
Bz-DL-Ala-COOH 3100 	3200 
Z-Ala-Ala-DL-Abu-COOEt 	0.12 0.15 
Z-Ala-Ala-DL-Abu-COOBz1 0.09 	 0.08 




A crystal structure of one a-ketoester bound into the active site of PPE has been completed in the Meyer 
laboratory and a schematic drawing of the interactions observed is shown below. The Ser-195 oxygen has 
added to the carbonyl group of the ketoester to form a tetrahedral intermediate which is stabilized by 
interactions with the oxyanion hole. This structure resembles the tetrahedral intermediate involved in peptide 
bond hydrolysis and proves that a-ketoesters are transition-state analogs. His-57 is hydrogen bonded to the 
carbonyl group of the ester functional group, the peptide backbone on a section of PPE's backbone hydrogen 
bonds to the inhibitor to form a 13-sheet, and the benzyl ester is directed toward the S' subsites. It appears 
likely that the potency of this class of inhibitor could be substantially improved if the structure was extended to 
allow for more interactions with the S' subsites. 
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Animal Studies With Elastase Inhibitors. The Boston University group has tested 13 inhibitors 
in the hamster model and have published the results on 6 inhibitors. They propose that the in vivo 
effectiveness of a new elastase inhibitor can be predicted from in vitro inhibitor data and its clearance rate from 
the lungs. The in vitro assay uses 3H-elastin as a substrate in a physiologic buffer containing protein (bovine 
serum albumin). Incubation of the inhibitor with HNE in the presence of the substrate takes place for 4 hr at 
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The Boston U. group classify the inhibitors into four categories. The first category includes inhibitors 
that are sparingly soluble in saline (approximately 1 mM or less) and are ineffective in vivo. For example, 
more than a 30:1 molar ratio of the poorly water soluble elastase inhibitor 3-chloroisocoumarin was required to 
achieve 50% inhibition of HNE in the in vitro elastin assay system. They predict that an amount of this 
inhibitor exceeding its solubility (1 mM in saline) would be required to obtain a 50% inhibition of instilled 
HNE in the hamster model, while allowing for clearance of much of the inhibitor during the 1 hr interval 
between instillation of inhibitor and HNE. Indeed they were not surprised that this compound was ineffective 
in preventing HNE-induced emphysema in the hamster (unpublished data). Possible reasons for the 
ineffectiveness of this category of inhibitors include their poor inhibition of HNE in saline solutions and/or the 
rapid clearance that is known to be associated with lipophilic compounds (Schanker, 1978). 
The second category of elastase inhibitors includes irreversible inhibitors such as Suc-Ala-Ala-Pro-Val-
CH2C1 (a peptide chloromethyl ketone, Lucey et al., 1989) and al-PI (Stone et al., 1990b). The third 
category comprises tight binding but slowly reversible inhibitors that clear relatively slowly from the lungs. 
Human secretory leukocyte protease inhibitor (SLPI) and eglin-c (Snider et al., 1985; Lucey et al., 1990a) clear 
slowly, at least in part due to their molecular size; however, this category also includes low molecular weight 
inhibitors that clear slowly because of their hydrophilicity (Kennedy et al., 1987). Members of both the second 
and third categories show a dose-response relation in ameliorating emphysema in the hamster, compounds in 
the second category also demonstrate a correlation between in vitro inhibitory activity against HNE-induced 
elastin solubilization and the in vivo amelioration of emphysema. 
Results with MeO-Suc-Ala-Ala-Pro-D,L-boro-Val pinacol ester (BOROVAL, Stone et al., 1990a) 
suggest a fourth category of inhibitors. BOROVAL is a highly effective but reversible transition state inhibitor 
of both PPE and HNE, and has been shown to prevent PPE-induced emphysema in hamsters. But 
pretreatment with as much as a 170-fold molar excess of BOROVAL, given intratracheally 1 h before 0.3 mg 
HNE, did not prevent emphysema. Indeed, lung volumes were larger after the BOROVAL pretreatment than 
after HNE alone. Emphysema was also induced by instilling HNE that had been mixed with and inactivated by 
a 41-fold molar excess of BOROVAL. Two hr after instillation of 0.3 mg HNE inactivated with a 34-fold 
molar excess of BOROVAL, bronchoalveolar lavage contained elastolytic activity but no evidence of 
hemorrhage. In contrast hemorrhage was severe in hamsters that had been instilled with 0.3 mg HNE alone. 
From these studies, it was concluded that BOROVAL can enhance HNE-induced emphysema. 
BOROVAL is soluble in saline, highly reversible (k off = 0.00038 sec-1 ) and rapidly cleared (t112 = 15 min in 
the lavageable compartment of the lungs). The Boston U. group postulate that BOROVAL suppresses HNE-
induced hemorrhage and the resultant influx of plasma protease inhibitors; the HNE-BOROVAL complex is 
transported into the alveolar interstitium, followed by dissociation of the inhibitor from the active site of HNE. 
Due to its small size, free BOROVAL is rapidly cleared and the reactivated HNE attacks elastic fibers giving 
rise to emphysema. If HNE plays a major role in the pathogenesis of emphysema and it enters the interstitium 
after release by neutrophils in the airways, then the administration of a reversible, rapidly cleared inhibitor to 
patents could exacerbate the emphysema. 
Acute Lung Injury Induced by Pulmonary Neutrophilia. In order to better understand the 
interactions among the alveolar wall, pulmonary neutrophil, enzyme release, acute lung injury and airspace 
enlargement, the Boston U. group developed a model of pulmonary neutrophilia induced by intratracheal 
instillation of E. coli lipopolysaccharide (LPS) in hamsters. The instillation of 10-100 ug of LPS induces 
pulmonary neutrophilia, which peaks at about 24 hrs; 75-100 x 106 neutrophils (PMN) are recoverable by 
bronchoalveolar lavage (BAL). There is also evidence of acute lung injury as indicated by the presence of 
blood and increased proteins in the BAL fluid; elastolytic activity measured with tntiated elastin as substrate is 
not present in BAL. The intratracheal instillation of CHO-Met-Leu-Phe at 24 hrs does not give rise to further 
increase in BAL PMN counts, but results in measurable elastolytic activity and an increase in blood and protein 
in the BAL fluid. Beta-glucuronidase, an index of PMN degranulation, is increased in the BAL fluid after 
CHO-Met-Leu-Phe treatment. There is an approximately 20% increase in mean linear intercept at 28-32 hrs 
after administration of LPS; the airspace enlargement is not enhanced by administration of CHO-Met-Leu-Phe 
at 24 hrs. 
Instillation of recombinant human al-PI or SLPI with the CHO-Met-Leu-Phe prevents the increase in 
blood and protein in the BAL fluid; that neutrophil degranulation is not affected is indicated by absence of 
change in the level of the BAL beta-glucuronidase. We proposed to use this model to test the efficacy of 
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elastase inhibitors in protecting against the induction of acute lung injury by degranulation of the animals' own 
pulmonary neutrophils. It may also prove useful as a model for testing these agents for their effects in 
protecting against PMN-induced respiratory airspace enlargement. 
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D. EXPERIMENTAL DESIGN AND METHODS. 
The proposed research represents an integrated proposal from three quite different research groups. 
The PI's laboratory will carry out the design and synthesis of all new inhibitors structures, study their 
inhibition mechanism in vitro, and measure their inhibitory potency in vitro. He will also study the interaction 
of the oxidizable inhibitors with myeloperoxidase. The Meyer group will carry out x-ray crystallographic 
studies with the elastase inhibitors using HNE and PPE, and will model new inhibitor structures (along with 
the PI) into the active site of both PPE and HLE. The Boston U. group will assay appropriate elastase 
inhibitors in vivo in the elastin assay and will perform all the proposed animal studies. The results from the 
animal studies will be feedback into the design and synthesis activities to produce improved generations of 
inhibitors for further animal studies. 
1. 	Develop and Synthesize Potent Synthetic Elastase Inhibitors Which Lose Their 
Inhibitory Potency Upon Oxidation. 
Most of the low-molecular weight inhibitors which have been developed by the academic and industrial 
investigators are stable toward oxidation by biological systems. And yet, the natural inhibitor of HNE, al-PI 
is inactivated by oxidation due to the presence of Met-358 in active site of al-PI. We believe that this 
susceptibility to oxidation is essential for the neutrophil's ability to migrate to sites of infection and attack 
invading microbes. We propose to develop low molecular wt. inhibitors of HNE which lose their elastase 
inhibitory ability upon oxidation. Once the design principles for this type of inhibitor are developed, we feel 
that pharmaceutical companies will add such structural features to the drugs currently under development. 
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Specific Aims. The major specific aim of our proposed research was the development of a 
synthetic elastase inhibitor which would be useful for the treatment of human emphysema. A variety of 
inhibitor structures were proposed including heterocyclic mechanism-based inhibitors and peptide 
transition state analogs. We proposed to test the specificity of all new inhibitors with other PMN proteases 
such as human leukocyte cathepsin G. A secondary goal of the research was the extension of potent 
inhibitor structures to other serine proteases. We suggested that inhibitor studies would lead to a better 
understanding of the active site structures of the serine proteases involved in connective tissue turnover, 
might produce clinically useful drugs for the treatment of emphysema and related diseases, would 
stimulate the research of medicinal chemists in pharmaceutical companies, and will provide new tools for 
the in vivo and in vitro study of the role of neutrophil and mast cell proteases in a variety of physiological 
processes. 
Summary of progress. During the 5 year period of this research project, we have developed 
several new classes of inhibitors for HNE including isocoumarins (mechanism-based inhibitors), peptide 
a-ketoesters (transition-state analogs), and peptide phosphonates (irreversible transition-state inhibitors). 
X-ray structural studies have been accomplished with 5 isocoumarin inhibitors bound to the active sites of 
PP elastase and trypsin, with 4 chloromethyl ketone inhibitors bound to the active site of HNE, and with 
one peptide a-ketoester inhibitor bound to the active site of PP elastase. The structural studies have led to 
a better understanding of the active site structures of these two important elastases and their mechanisms of 
inhibition. Several of the isocoumarin inhibitors developed have been studied with other physiologically 
important serine proteases and an influenza viral serine esterase. One of our inhibitors, 3,4- 
dichloroisocoumarin, is now commercially available from four companies for use as a general serine 
protease inhibitor. Isocoumarin and phosphonate inhibitors may prove to be valuable in other disease 
states related to serine protease activity and are currently being tested in animal models of sepsis and 
Alzheimer's disease. 
The various classes of elastase inhibitors discovered in my laboratory have been used extensively 
by pharmaceutical companies in the development of therapeutics for the treatment of emphysema. In 
particular, the chloromethyl ketone inhibitor Me0-Suc-Ala-Ala-Pro-Val-CH2C1 is used as the standard 
elastase inhibitor for the validation of new animal models of emphysema and as a standard elastase 
inhibitor to compare the effectiveness of newly developed inhibitors (Fletcher et al., 1990). 
Benzoxazinones and peptide a-ketoesters elastase inhibitors, discovered in my laboratory, have been 
chosen by Syntex Canada (Krantz et al., 1987; 1990) and Merrill Dow (Peet et al., 1990) for extensive 
development. Peptide sequences which we discovered to be potent elastase inhibitors have been translated 
into the sequences found in the potent trifluoromethyl ketone inhibitors of fiN elastase which are now 
undergoing development by ICI Americas as therapeutics (Trainor, 1987). The trifluoromethyl ketone 
class of elastase inhibitors is probably the closest to reaching clinical use of any of the low molecular 
weight inhibitors available today and at least one derivative is undergoing phase I testing. 
Isocoumarin Mechanism-Based Inhibitors. Isocoumarins are mechanism-based (or 
suicide) heterocyclic serine proteases which are rich in possible masked reactive functional groups. Thus 
far, we have described isocoumarins which contain latent acid chloride or quinone imine methide 
functional groups. We have synthesized well over a hundred isocoumarin inhibitors, have published ca. 
13 papers and reviews which describe these inhibitors (see publication list at end of this section) and have 
still have not yet reported the majority of the compounds which we have synthesized. The recent 
completion of several x-ray structures of complexes of PPE inhibited by isocoumarins has yielded 
important insights into the binding modes of these inhibitors and we are working on two additional x-ray 





the study of an influenza viral esterase and a group of serine proteases isolated from natural killer cells 
(publication 4, 8, 13, 14). 
The inactivation mechanism of serine proteases by 3-alkoxy-7-amino-4-chloroisocoumarins (1) is 
shown below. The active site Ser-195 attacks the isocoumarin carbonyl group and opens the isocoumarin 
ring to form an acyl enzyme (2). This reaction unmasks a latent quinone imine methide functional group 
(3) which is formed by the elimination of HC1 from the acyl enzyme. This can react either with an enzyme 
nucleophile (His-57) to give an irreversibly inhibited enzyme structure (4) or with a solvent nucleophile to 
give a stable acyl enzyme (5). Partial reactivation by hydroxylamine with some inhibited derivatives 
suggests a partitioning between the two enzyme-inhibitor complexes (4 & 5) in solution with the 
nonreactivatable complex (4) containing an alkylated histidine residue. Both the 7-amino and 4-chloro 
groups are required for formation of a stable inactivated enzyme; isocoumarins which lack these features 
inhibit serine proteases, but deacylate fairly rapidly. 
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In addition to the kinetic evidence, the proposed inhibition mechanism is supported by x-ray 
crystallographic studies. Five enzyme-isocoumarin complexes have completed in collaboration with Ed 
Meyer (Texas A & M) and Wolfram Bode (Max Planck Institute, Munich) and are listed below. 
7-amino-4-chloro-3-methoxyisocoumarin & PPE - solvolysis product 5 with Nu = acetate -
(structure published, Meyer et al., 1987). 
4-chloro-3-ethoxy-7-guaniclinoisocoumarin & PPE - acyl enzyme 2 with chlorine still present -
structure published in 1990, publication 2. 
4-chloro-3-ethoxy-7-guanidinoisocoumarin & trypsin - mixture of acyl enzyme 2 and the histidine 
alkylation product 4 - structure published in J. Am. Chem. Soc. 
7-amino-3-bromoethoxy-4-chloroisocoumarin & PPE - histidine alkylation product 4 - structure 
published. 
7-(Tos-Phe-NH)-4-chloro-3-ethoxyisocoumarin & PPE - histidine alkylation product 4 - structure 
complete and will be submitted soon. 
All the major products (2, 4, and 5) in the reaction scheme have been observed 
crystallographically with different isocoumarins. The observation of the doubly covalent bond histidine 
alkylation product 4 is the second time such a derivative has been observed with a serine protease. The 
first doubly covalently bound adduct was observed in a crystal structure of PPE inhibited by a 13-lactam 
inhibitor which was reported by a Merck group (Navia et al., 1987). The exact product formed in the 
inhibition reaction varies with both the enzyme and the isocoumarin inhibitor. Different inhibitors give 
variable ratios of hydroxylamine reactivatable acyl enzymes (2 or 5) or non-reactivatable alkylation 
products (4). The solvolysis product 5 is probably an artifact of that particular crystallographic 




protonated and less likely to undergo alkylation. Kinetic studies with a variety of inhibitors indicate that 
histidine alkylation is usually the favored product at neutral pH with both elastases and most of the 
isocoumarins studied. 
Isocoumarin Binding Modes. The binding modes of all five isocoumarins complexed to PPE 
and trypsin are remarkably different even though all are tethered to Ser-195 via an ester bond. The 
carbonyl group of the ester bond linking Ser-195 to the inhibitor is in the oxyanion hole of the serine 
protease in the 7-amino-4-chloro-3-methoxyisocoumarin complex with PPE, while it is twisted out of the 
oxyanion hole in the 7-guanidino structure. The twisting of the ester carbonyl group allows favorable 
hydrogen bonding between the 7-guanidino group and Thr-41 (6) and explains the stability of the complex 
toward deacylation. His-57 is either hydrogen bonded to the ester bond or is covalently linked with the 
inhibitor (4). 
Schematic drawings of the interactions observed in the PPE complexes with 4-chloro-3-ethoxy-7- 
guanidinoisocoumarin (6) and the 3-bromoethoxyisocoumarin (7) are shown below and a stereo drawing 
of 3 heterocyclic inhibitors superimposed in the active site of PPE is shown in Fig. 11 of publication 9. In 
the four PPE complexes, the 3-alkoxy group of the isocoumarin is either in the Si pocket or lying nearby. 
However in the complex of trypsin with 4-chloro-3-ethoxy-7-guanidinoisocoumarin, the 7-guanidino 
group of the isocoumarin is inserted into the Si pocket of trypsin to interact with Asp-189 in trypsin's 
binding pocket, while the 3-alkoxy group points toward the S' subsites of the enzyme. This orientation is 
almost 180° from the orientation found in the complex of the same compound with PPE (6). Thus a 
significantly different binding geometry has been observed for the first time when the same inhibitor is 
examined with different two serine proteases. It is clear that we don't know all the rules for predicting the 
preferred binding conformation of a small molecule inhibitor to the active site of a serine protease. 





Molecular Modeling and Inhibitor Design. Although it is not yet possible to predict the 
binding mode of a new isocoumarin inhibitor to elastase, molecular modeling with x-ray crystal structures 
is extremely useful for improving that inhibitor and for interpreting inhibition kinetic data obtained with 
related inhibitor structures. For example, molecular modeling of the 7-guanidinoisocoumarin PPE 
complex 6 suggested that the addition of a small alkyl group (t-butyl) to the guanidino group might 
increase affinity to the enzyme due to the presence of a small hydrophobic pocket near the terminal 
nitrogen of guanidino group and above Thr-41. Therefore, we synthesized a series of 7-alkyl-NH-CO-
NH- derivatives of 4-chloro-3-ethoxyisocoumarin. These ureas were chosen for synthesis due to the 
difficulty of synthesizing alkyl guanidino derivatives. Replacement of the 7-guanidino group by a urea 
functional group resulted in almost no loss of inhibitory potency (see following table). As predicted, the t-
butyl-NH-CO-NH- derivative was the most effective PPE inhibitor and had a second order inhibition rate 
kobsd/[I] which was 3.5 fold higher than the parent inhibitor. Indeed, the compounds developed from the 
modeling are among the best irreversible inhibitors reported thus far for PPE (work is described in 
publication 2). In order to confirm the binding mode predicted from molecular modeling, the Meyer group 
is currently determining the structure of PPE inhibited by 7-(t-Bu-HN-CO-NH)-EtOIC. 
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7-(H2N-C(=NH2+)-NH)-EtOIC 	 2300M- ls-1 
7-(H2N-CO-NH)-EtOIC 2200 
7-(Me-HN-CO-NH)-EtOIC 	 1400 
7-(Et-HN-CO-NH)-EtOIC 1700 	 EtOIC = 
7-(i-Pr-HN-CO-NH)-EtOIC 	 4900 4-chloro- 
7-(t-Bu-HN-CO-NH)-EtOIC 8100 	 3-ethoxy 
7-(Ph-HN-CO-NH)-EtOIC 	 4200 isocoumarin 
One we realized that the 3-alkoxy group of the isocoumarin was fitting into the S1 pocket of 
elastase, we synthesized a number of derivatives with 3-alkoxy groups of varying length. With HNE, we 
found the following inhibition constants: MeO, 10,000; EtO, 9,400; PrO, 54,000; and bromoethoxy, 
200,000. Clearly HNE prefers the long alkoxy groups. The structure determination of the complex of the 
3-bromoethoxyisocoumarin (7) with PPE has allowed us to interpret our kinetic data with PPE (see 
following table, all the bromoethoxy derivatives are ca. 100 fold better with HNE, data not shown). First 
it is clear that the bromopropoxy derivatives with a slightly long alkoxy group are over 100 fold poorer 
inhibitors of PPE and HNE. All of the derivatives in which a hydrophobic group is placed on the 7-amino 
group are 3-7 fold better inhibitors than the parent with the exception of the phenyl urea derivative which is 
much poorer. The 7-amino group of the isocoumarin points toward the S' subsites of PPE and HNE and 
we predict that the hydrophobic groups in the extended inhibitors are interacting with the S2' subsite (Leu-
143, Leu-151, Thr-41 in PPE). The phenyl urea derivative is probably so rigid, that the 7-substituent 














Human Neutrophil Elastase Inhibitors. Unfortunately, no crystal structures of an 
isocoumarin bound to HNE is available or likely to become available. Wolfram Bode and the Merck group 
have tried extensively to crystallize complexes of HNE bound to small molecule inhibitors. Up to the 
present, the smallest inhibitor which has yielded crystals with HNE is a tetrapeptide such as Me0-Suc-Ala-
Ala-Pro-Val-CH2C1. However, the crystal structures obtained with PPE have been invaluable for 
modeling with HNE. The active site structures of PPE and HNE have many features in common (see the 
review, publication 9) and so we feel quite comfortable using the PPE crystal structures for modeling with 
HNE. For example, the complex of the 7-Tos-Phe derivative of 4-chloro-3-ethoxyisocoumarin has been 
determined and has the 3-alkoxy group in the S1 pocket and the Tos-Phe group interacting with the S' 
subsites of PPE (shown below left). Representative inhibition rates with HNE are shown below (right). 
The derivatives shown all have a 3-propoxy group instead of the 3-ethoxy group shown in the crystal 
structure since we demonstrate that HNE preferred to an alkoxy group with one more methylene group. 
Clearly, most of the rates are so fast that the rate constants should be considered to be lower limits. 
The active site of HNE is much more hydrophobic than that of PPE. Two significant changes are: 
Thr-41 in PPE is replaced in HNE by Phe-41 and Gln-192 is changed to Phe-192. Molecular modeling 
with HNE indicates that the Tos-Phe group is interacting with the S' subsites consisting of the side chains 
of Phe-41, Leu-35, and Leu-143. Clearly all the hydrophobic 7-substituents are making favorable 














S 1 subsite 	 PhNHCO 143,000 S' subsites PhCH2NHCS 	>131,000 
Ph-HNCS >166,000 
Dichloroisocoumarin. We should also mention 3,4-dichloroisocoumarin which we reported as 
a general serine protease inhibitor in 1985 (publication 29). HLE and PPE are both inhibited effectively by 
3,4-dichloroisocoumarin with kobsd/[I] values of 8900 and 2500 M -1 s-1 respectively. Although the 
elastases are most effectively inhibited, dichloroisocoumarin is a general serine protease inhibitor and 
reacts with all serine proteases which have been investigated thus far. It is now commercially available 
from four companies and is becoming widely used for diagnosing new serine proteases since it is more 
reactive than PMSF and less hazardous than DFP. It addition it has also been invaluable to show that 
serine proteases are involved in natural killer cell and cytotoxic T lymphocyte granule mediated killing of 
targeted cells (publications 4, 13, 14). I expect to see this inhibitor increasingly used by other 
investigators in the future. 
Peptide Phosphonate Inhibitors. Peptidyl derivatives of a-aminoalkylphosphonate diphenyl 
ester are effective and specific inhibitors of serine proteases at low concentrations. These inhibitors are 
chemically stable, relatively easy to synthesize, and do not react with acetylcholinesterase. Previously 
synthesized phosphonate inhibitors of serine proteases include phosphonyl fluorides or phosphonamides 
which are unstable in solution and/or reactive toward acetylcholinesterase. Our phosphonate diphenyl 
esters form very stable derivatives with serine proteases due to the resemblance between the inhibition 
product (phosphonyl derivative shown below) and the tetrahedral intermediate involved in peptide bond 
hydrolysis. Our phosphonates are stable for at least 3 days in human plasma and the inhibited enzyme has 
a half-life for reactivation of 10 hrs in the case of chymotrypsin and >3 days in the case of the elastases. 
Although phosphonates are not as reactive as isocoumarins, we believe that they have considerable utility 
as therapeutic agents due their high stability and specificity. 
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Aminoalkylphosphonate diphenyl esters are very specific for the target serine protease and the data 
suggests that good interactions with the S1 pocket of the target serine protease are necessary before 
nucleophilic substitution on phosphorus atom occurs to give a stable phosphonyl derivative. For example, 
Suc-Val-Pro-PheP(OPh)2 reacts with chymotrypsin (kqsd/[i] = 44,000 M -1 s-1 ) and does not react with 
elastases. Boc-Val-Pro-ValP(OPh)2 reacts with HNE ( 7,000 M-1  s-1 )and PPE (11,000 M-1  s-1)and 








phenylalanine are also inhibitors for other chymotrypsin-like enzymes such as rat mast cell protease II and 












The inhibition reaction is stereospecific since 31P NMR studies have shown than only one of the 
two stereoisomers of Suc-Val-Pro-PheP(OPh)2 reacts with chymotrypsin with a rate constant which is 
higher than (146,000 M- ls-1 ) the mixture. The 31P NMR of chymotrypsin inhibited by this peptide 
shows one broad signal at 25.98 ppm corresponding to the Ser-195 phosphonate ester which is consistent 
with the product structure shown above. 
Peptide a-Ketoester Transition-State Inhibitors. A variety of transition-state inhibitors 
for elastase are currently available including peptide aldehydes, peptide boronic acids, and peptide 
trifluoromethyl ketones. During the course of this research, we developed novel peptide a-ketoesters as 
another type of transition-state inhibitor for elastases. This class of inhibitors was based on the refined x-
ray crystal structure of the complex formed between bovine trypsin and the ketoacid inhibitor 4- 
amidinophenylpyruvate (APPA), a potent trypsin inhibitor (Walter and Bode, 1983). In the x-ray 
structure, the amidinophenyl group is located in the primary specificity pocket of trypsin and the active site 
serine has added to the 2-carbonyl group in APPA. The oxyanion is stabilized by hydrogen bonding with 
groups in the oxyanion hole of trypsin. A unique feature of this structure is the hydrogen bonding 
observed between the carboxylate oxygen and the serine oxygen and the NH of histidine-57. We expected 
that the negative charge on the carboxylate would significantly contribute to the binding energy of a-
ketoacids. 
We designed and synthesized a number of peptide derivatives of various a-ketoacids and a-
ketoesters derived from several different amino acids. Some of our kinetic results are shown in the 
following table where K1 values are report in piVi in 0.1 M Hepes, pH 7.5, 0.5 M NaC1, 9.0-9.8% 
Me2S0 at 25°C (Ala-CO2Et = -NHCH(CH3)CO-CO2Et; Abu = 2-aminobutanoic acid). Surprisingly, the 
a-ketoesters are much better inhibitors than the corresponding acids which indicates that additional 
interactions with the Si' subsite and hydrogen bonding of the ester oxygen with the histidine N-H can 
result in significant binding energy in the case of elastase. The best inhibitors, Z-Ala-Ala-DL-Abu-
COOEt, the corresponding benzyl ester, and Z-Ala-Ala-Ala-DL-Ala-COOEt, had IQ values in the 
submicromolar range (publication 28). Importantly, MeO-Suc-Val-Pro-Phe-COOMe is one of the most 
potent reversible cathepsin G inhibitors known. 
Inhibitor 	 HLE 	PPE 	 Cat G 
	
Bz-DL-Ala-COOEt 	640 µM 590 
Bz-DL-Ala-COOH 3100 	3200 
Z-Ala-Ala-DL-Abu-COOEt 	0.12 0.15 
Z-Ala-Ala-DL-Abu-COOBz1 0.09 	 0.08 
Z-Ala-Ala-Ala-DL-Ala-COOEt 	0.3 0.14 
MeO-Suc-Val-Pro-DL-Phe-COOMe 1.1 
ChyT 	PPE 	HNE 
50 4200 380 
15 	2800 	1500 
2,000 NI NI 
21 	7,100 	7,100 
1,500 740 140 
11,000 	NI 	NI 
570 44 53 
15 	1.6 	1.6 
NI 11,000 27,000 
17,000 	NI 	NI 
44,000 NI NI 
A crystal structure of one a-ketoester bound into the active site of PPE has been completed in the 
Meyer laboratory and a schematic drawing of the interactions observed is shown below. The Ser-195 
oxygen has added to the carbonyl group of the ketoester to form a tetrahedral intermediate which is 
stabilized by interactions with the oxyanion hole. This structure resembles the tetrahedral intermediate 
involved in peptide bond hydrolysis and proves that a-ketoesters are transition-state analogs. His-57 is 
hydrogen bonded to the carbonyl group of the ester functional group, the peptide backbone on a section of 
PPE's backbone hydrogen bonds to the inhibitor to form a (3-sheet, and the benzyl ester is directed toward 
the S' subsites. It appears likely that the potency of this class of inhibitor could be substantially improved 
if the structure was extended to allow for more interactions with the S' subsites. 
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